Aeolus Announces Publication of Data

Aeolus Pharmaceuticals (OTCQB:AOLS) shared the publication of a study in a peer-reviewed journal demonstrating that AEOL 10150 improves survival and protects against brain damage and oxidative stress caused by seizures after pilocarpine exposure.
As quoted in the press release:

In studies conducted by researchers, led by Manisha Patel, PhD, at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Anschutz Medial Campus rats receiving AEOL 10150 and atropine plus diazepam, the current standard of care (“SOC”), after exposure to the nerve agent surrogate pilocarpine, had statistically significant higher rates of survival and lower levels of brain damage caused by oxidative damage and associated inflammation than animals receiving the SOC alone. The studies were conducted under a grant from the National Institutes of Health Countermeasures Against Chemical Threats (“NIH CounterACT”) group.
“While the current standard of care improves survival after nerve agent exposure, treated survivors experience neuronal damage and associated cognitive decline and additional mortality is seen,” stated Manisha Patel, PhD, of the University of Colorado Anschutz Medical Campus.

Click here to read the full press release.

Source: www.accesswire.com